Hepion Pharmaceuticals, Inc. (HEPA) financial statements (2022 and earlier)

Company profile

Business Address 399 THORNALL STREET
EDISON, NJ 08837
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
6/30/2017
6/30/2016
6/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 40,72713,9232,83212,9837,4044,563
Cash and cash equivalents 40,72713,9232,83212,9837,4044,563
Prepaid expense 1,907466136210491681
Total current assets: 42,63414,3892,96813,1937,8955,244
Noncurrent Assets
Operating lease, right-of-use asset 556798
Property, plant and equipment 1085732688181
Intangible assets, net (including goodwill) 5,0615,0615,0615,0615,061 
Goodwill 1,8711,8711,8711,8711,871 
Intangible assets, net (excluding goodwill) 3,1903,1903,1903,1903,190 
Other undisclosed noncurrent assets 285128128637051
Total noncurrent assets: 6,0116,0445,2215,1925,212133
TOTAL ASSETS: 48,64520,4338,18918,38513,1075,377
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 4,3829851,4102,9455,0731,938
Accounts payable 3,7224927481,6274,2521,481
Accrued liabilities 6604946611,318821457
Debt  2671,440 10 
Other undisclosed current liabilities 280     
Total current liabilities: 4,6621,2522,8502,9455,0841,938
Noncurrent Liabilities
Long-term debt and lease obligation 472541    
Long-term debt, excluding current maturities 177     
Operating lease, liability 296541
Liabilities, other than long-term debt 2,9912,4543,3646,3826,706 
Deferred revenue and credits9   
Deferred tax liabilities, net3611,2701,270 
Deferred income tax liabilities 40919
Business combination, contingent consideration, liability 2,5702,4302,5903,4103,320 
Derivative instruments and hedges, liabilities 1264041,7022,116 
Total noncurrent liabilities: 3,4632,9953,3646,3826,706 
Total liabilities: 8,1254,2476,2149,32711,7891,938
Stockholders' equity
Stockholders' equity attributable to parent, including: 40,52016,1861,9759,0581,3183,439
Common stock 302832
Additional paid in capital 142,91197,65176,65167,51432,22717,351
Accumulated deficit (104,105)(83,186)(76,464)(59,504)(44,612)(27,614)
Other undisclosed stockholders' equity attributable to parent 1,7121,7201,7861,04013,70013,700
Total stockholders' equity: 40,52016,1861,9759,0581,3183,439
TOTAL LIABILITIES AND EQUITY: 48,64520,4338,18918,38513,1075,377

Income statement (P&L) ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
6/30/2017
6/30/2016
6/30/2015
Operating expenses (20,146)(7,770)(14,594)(21,024)(20,805)(13,960)
Operating loss: (20,146)(7,770)(14,594)(21,024)(20,805)(13,960)
Nonoperating income (expense)    4,2253,807(388)
Interest and debt expense (31)(555)(339)   
Loss from continuing operations before equity method investments, income taxes: (20,177)(8,325)(14,933)(16,799)(16,999)(14,348)
Other undisclosed income (loss) from continuing operations before income taxes (146)3794,948   
Loss from continuing operations before income taxes: (20,323)(7,946)(9,985)(16,799)(16,999)(14,348)
Income tax expense (benefit) (31)1,2275361,908  
Net loss attributable to parent: (20,354)(6,719)(9,449)(14,891)(16,999)(14,348)
Preferred stock dividends and other adjustments      (7,845)
Other undisclosed net loss available to common stockholders, basic (5)(5,443)(8,452)   
Net loss available to common stockholders, basic: (20,359)(12,162)(17,901)(14,891)(16,999)(22,193)
Other undisclosed net loss available to common stockholders, diluted    (2,698)  
Net loss available to common stockholders, diluted: (20,359)(12,162)(17,901)(17,589)(16,999)(22,193)

Comprehensive Income ($ in thousands)

9/30/2021
TTM
12/31/2020
12/31/2019
12/31/2018
6/30/2017
6/30/2016
6/30/2015
Net loss: (20,354)(6,719)(9,449)(14,891)(16,999)(14,348)
Comprehensive loss, net of tax, attributable to parent: (20,354)(6,719)(9,449)(14,891)(16,999)(14,348)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: